3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Sinonasal Squamous Cell Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Oropharyngeal Neoplasms
1
Melanoma
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Exostoses, Multiple Hereditary
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Clinical Stage I Gastric Cancer AJCC v8
1
Breast Cancer Lymphedema
1
BTC
1
Interventions
Gemcitabine
13
Magnetic Resonance Spectroscopy
11
Cisplatin
9
Specimen Handling
8
pembrolizumab
6
Radiation
5
Mitomycin
5
Fluorouracil
5
Cystoscopy
5
enfortumab vedotin
4
Transurethral Resection of Bladder
4
Radiotherapy
4
Cystectomy
4
durvalumab
3
dehydroftorafur
3
avelumab
3
Platinum
3
Nivolumab
3
Mitozytrex
3
Carboplatin
3
1,2-diaminocyclohexaneplatinum II citrate
3
ulixertinib
2
tremelimumab
2
erdafitinib
2
atezolizumab
2
Radiotherapy, Intensity-Modulated
2
Radiosurgery
2
Paclitaxel
2
Immunoglobulin G
2
Docetaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Surgical Procedures, Operative
×
30 days
×
Clear all
NCT03924856
2026-05-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3
Completed
907 enrolled